Patients at high risk of recurrent venous thromboembolism after initial treatment with full-dose anticoagulants for 6–24 months were randomly assigned to either reduced-dose or full-dose apixaban or ...

Venous thromboembolism (VTE) risk varies across hormonal contraceptives, according to a research letter published online.

Venous Thromboembolism Treatment Market The venous Thromboembolism Treatment Market growth is driven by rising VTE prevalence, anticoagulan ...

Purpose Published evidence on the incidence and predictors of venous thromboembolism (VTE) in patients with cirrhosis of the liver is reviewed. Summary The frequently observed phenomenon of ...

According to GlobalData, the worldwide thrombectomy device market was worth $2.96 billion in 2024 and is set to register a ...

Inari’s expertise combined with Stryker’s existing distribution and logistics network could boost volume and procedure ...

Study shows how gender and age affect bleeding risk during anticoagulant treatment for venous thromboembolism, with key ...

Stryker has completed its $4.9 billion acquisition of Inari Medical, a company specializing in venous thromboembolism ...

Cerebral venous sinus thrombosis (CVST) is a rare form of stroke with female predominance. The clinical manifestations of CVST can vary vastly, thus delaying diagnosis and leading to significant ...

Hospital-based researchers from Denmark have reported a substantial increase in cardiovascular disease risk among male users ...

A woman’s risk for blood clots varied by the type of hormonal contraception used, according to a nationwide cohort study ...

Managing acute VTE risks in thrombocytopenia is challenging for clinicians, given the substantial gap in guidelines ...